Alterity Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class treatments for neurodegenerative diseases characterized by protein aggregation and abnormal metal homeostasis, with its lead candidate ATH434 designed to reduce α-synuclein accumulation by functioning as an iron chaperone in the central nervous system. The company's pipeline is focused primarily on Multiple System Atrophy (MSA) and Parkinson's disease, with earlier-stage research in Huntington's disease, Friedreich's ataxia, Alzheimer's disease, and related neurological conditions. Alterity currently generates no product revenue as a clinical-stage company and instead funds operations through research grants and collaborations with academic institutions, while maintaining an intellectual property portfolio covering iron-modulating compounds and zinc ionophores, with revenue opportunities available through royalties on licensed assets.